Publication
Title
Autocrine signaling in cardiac remodeling : a rich source of therapeutic targets
Author
Abstract
The myocardium consists of different cell types, of which endothelial cells, cardiomyocytes, and fibroblasts are the most abundant. Communication between these different cell types, also called paracrine signaling, is essential for normal cardiac function, but also important in cardiac remodeling and heart failure. Systematic studies on the expression of ligands and their corresponding receptors in different cell types showed that for 60% of the expressed ligands in a particular cell, the receptor is also expressed. The fact that many ligand-receptor pairs are present in most cells, including the major cell types in the heart, indicates that autocrine signaling is a widespread phenomenon. Autocrine signaling in cardiac remodeling and heart failure is involved in all pathophysiological mechanisms generally observed: hypertrophy, fibrosis, angiogenesis, cell survival, and inflammation. Herein, we review ligand-receptor pairs present in the major cardiac cell types based on RNA-sequencing expression databases, and we review current literature on extracellular signaling proteins with an autocrine function in the heart; these include C-type natriuretic peptide, fibroblast growth factors 2, F21, and 23, macrophage migration inhibitory factor, heparin binding-epidermal growth factor, angiopoietin-like protein 2, leptin, adiponectin, follistatin-like 1, apelin, neuregulin 1, vascular endothelial growth factor, transforming growth factor beta, wingless-type integration site family, member 1-induced secreted protein-1, interleukin 11, connective tissue growth factor/cellular communication network factor, and calcitonin gene-related peptide. The large number of autocrine signaling factors that have been studied in the literature supports the concept that autocrine signaling is an essential part of myocardial biology and disease.
Language
English
Source (journal)
Journal of the American Heart Association : Cardiovascular and cerebrovascular disease / American Heart Association; American Stroke Association. - [Hoboken, NJ], 2012, currens
Publication
[Hoboken, NJ] : John Wiley & Sons , 2021
ISSN
2047-9980
DOI
10.1161/JAHA.120.019169
Volume/pages
10 :3 (2021) , 28 p.
Article Reference
e019169
ISI
000637752200034
Pubmed ID
33470124
Medium
E-only publicatie
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Project info
Activating the neuregulin-1/ErbB4 pathway for treatment of heart failure.
Studies of the ErbB4 receptor in myocardial non-myocytes to create new opportunities for the treatment of cardiac disease.
Development of ErbB4 Agonists for Treatment of Heart Failure.
Identification of small molecule ErbB4 agonist for treatment of heart failure, diabetic kidney injury and fibrotic disorders.
Defining atrial myopathy in aging and disease (DIAMOND consortium).
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 31.05.2021
Last edited 21.11.2024
To cite this reference